This report provides comprehensive information on the therapeutic development for Nephrotic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephrotic Syndrome and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Nephrotic Syndrome Overview
- Therapeutics Development
- Pipeline Products for Nephrotic Syndrome - Overview
- Pipeline Products for Nephrotic Syndrome - Comparative Analysis
- Nephrotic Syndrome - Therapeutics under Development by Companies
- Nephrotic Syndrome - Therapeutics under Investigation by Universities/Institutes
- Nephrotic Syndrome Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Nephrotic Syndrome - Products under Development by Companies
- Nephrotic Syndrome - Products under Investigation by Universities/Institutes
- Nephrotic Syndrome - Companies Involved in Therapeutics Development
- Asahi Kasei Pharma Corp.
- Bristol-Myers Squibb Company
- Orbis Biosciences, Inc.
- Retrophin Inc.
For more information visit http://www.researchandmarkets.com/research/kqflnw/nephrotic